345 related articles for article (PubMed ID: 22820319)
41. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
42. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation.
Kim CK; Choi J; Kim HB; Callaway Z; Shin BM; Kim JT; Fujisawa T; Koh YY
J Pediatr; 2010 May; 156(5):749-54. PubMed ID: 20171653
[TBL] [Abstract][Full Text] [Related]
43. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
Winchester L; García L; García I; Concepción CB
P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
[TBL] [Abstract][Full Text] [Related]
44. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
45. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
[TBL] [Abstract][Full Text] [Related]
46. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
47. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
48. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
Groothuis JR; Simoes EA; Hemming VG
Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
[TBL] [Abstract][Full Text] [Related]
49. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].
Pinquier D; Gouyon JB; Fauroux B; Mons F; Vicaut E; Bendjenana H; Rouffiac E; Marret S; Aujard Y
Arch Pediatr; 2009 Nov; 16(11):1443-52. PubMed ID: 19767182
[TBL] [Abstract][Full Text] [Related]
50. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
Grupo de Hospitales Benazuza
An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
[TBL] [Abstract][Full Text] [Related]
51. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
52. Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective.
Tulloh RM; Bury S
Future Cardiol; 2014 Mar; 10(2):235-42. PubMed ID: 24762251
[TBL] [Abstract][Full Text] [Related]
53. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
54. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.
Beigelman A; Isaacson-Schmid M; Sajol G; Baty J; Rodriguez OM; Leege E; Lyons K; Schweiger TL; Zheng J; Schechtman KB; Castro M; Bacharier LB
J Allergy Clin Immunol; 2015 May; 135(5):1171-8.e1. PubMed ID: 25458910
[TBL] [Abstract][Full Text] [Related]
55. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I; Tough S; Gillis L; Majaesic C
Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
[TBL] [Abstract][Full Text] [Related]
56. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
57. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
[TBL] [Abstract][Full Text] [Related]
58. Airflow limitation during respiratory syncytial virus lower respiratory tract infection predicts recurrent wheezing.
Bont L; Van Aalderen WM; Versteegh J; Brus F; Draaisma JT; Pekelharing-Berghuis M; Van Diemen-Steenvoorde RA; Kimpen JL
Pediatr Infect Dis J; 2001 Mar; 20(3):277-82. PubMed ID: 11303830
[TBL] [Abstract][Full Text] [Related]
59. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
[TBL] [Abstract][Full Text] [Related]
60. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model.
Thomas NJ; Hollenbeak CS; Ceneviva GD; Geskey JM; Young MJ
J Pediatr Hematol Oncol; 2007 Apr; 29(4):227-32. PubMed ID: 17414564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]